Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.

Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.